The opportunity of obtaining pathological samples from a rare disease patient is extremely rare. Therefore, most of the current researches focus on the gene knockout mice models, however, what extent of these models can reflect the aspects of rare diseases is always difficult to be evaluated accurately.
During the past decade, the development of induced pluripotent stem cells (iPSCs) technology provides an overall new strategy to reproduce the pathological progress of diseases in a dish (1) . Human iPSCs can derived from many obtained somatic cells from patients such as surgically resected skin fibroblasts, blood mononuclear cells, urine cells or body liquid cells, et al. The iPSCs from rare disease patients have the capacity for self-renewal and pluripotency, theoretically are well suited to modeling the disease process of donors. Using the iPSCs-based models, a series of new molecular mechanisms of rare diseases has been identified (2). These in dish rare disease models are superior to other strategies in the following aspects: first, the most diseaseassociated cell types can be obtained step by step from iPSCs; secondly, the cell models carry all the genetic and even part of epigenetic information of the patients; thirdly, donor sources of iPSCs are safely, affordably, and always frequently obtained.
In this current issue, two original articles described their work on the establishment of rare diseases models. The use of patient-specific iPSCs for modeling rare diseases has demonstrated its potential to provide a better understanding of the exact pathological mechanisms of rare diseases, and is becoming more routine and more scalable. Intractable & Rare Diseases Research will continue to focus on more efforts to introduce most updated knowledge and original research in this field in the future.
